A meta-analysis that evaluated the effects of TTh evidenced an elevation of PSA, hematocrit, and bone mineral density, without major adverse cardiovascular events or prostate cancer, concluding that long-term TTh was safe, tolerable, and effective on metabolic outcomes [9]. This evidence concerns the gene KLK3 and prostate cancer.